Rational development of histone deacetylase inhibitors as anticancer agents: a review.
about
FOXP3 ensembles in T-cell regulationEmerging roles of lactic acid bacteria in protection against colorectal cancerHistone modifications, DNA methylation, and schizophreniaHistone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinomaRational design, synthesis and evaluation of first generation inhibitors of the Giardia lamblia fructose-1,6-biphosphate aldolaseSIRT3 and cancer: tumor promoter or suppressor?Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cellsComparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.Gene profile analysis of osteoblast genes differentially regulated by histone deacetylase inhibitors.Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.Vorinostat in solid and hematologic malignanciesPhase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.Valproate treatment of human cord blood CD4-positive effector T cells confers on them the molecular profile (microRNA signature and FOXP3 expression) of natural regulatory CD4-positive cells through inhibition of histone deacetylase.Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography.Synthesis and biological evaluation of triazol-4-ylphenyl-bearing histone deacetylase inhibitors as anticancer agentsHistones: Controlling Tumor Signaling CircuitryPharmacogenomics of mood stabilizers in the treatment of bipolar disorder.Histone deacetylase: a potential therapeutic target for fibrotic disordersEpigenetic targets of bioactive dietary components for cancer prevention and therapy.Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone lossHistone deacetylase enzymes as potential drug targets in cancer and parasitic diseases.Histone deacetylase regulation of immune gene expression in tumor cells.Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brainTreatment of chronic kidney diseases with histone deacetylase inhibitors.A liquid chromatography/tandem mass spectrometry assay to quantitate MS-275 in human plasma.Nonhistone protein acetylation as cancer therapy targets.Epigenetic alterations in ultraviolet radiation-induced skin carcinogenesis: interaction of bioactive dietary components on epigenetic targetsCancer epigenetics: above and beyondRegulation of immune responses by histone deacetylase inhibitorsThe synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo.Characterization of a gene cluster responsible for the biosynthesis of anticancer agent FK228 in Chromobacterium violaceum No. 968The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liverDesign, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.Targeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancerRaf kinases: oncogenesis and drug discovery.Hodgkin's lymphoma: molecular targets and novel treatment strategies.
P2860
Q24299602-54172210-93BA-4534-91C9-BB1997FDC1F5Q24563783-F939B9FD-9497-4F9A-AB18-9285411B148BQ24606593-CAB912BF-9897-4FD7-8103-C0B897162E46Q27025984-3B0E0C3D-7C06-4A59-A01F-9ACA3501D45BQ27666998-5C943FB5-C4BA-42AB-BDE8-DF26FDD67238Q28390097-AC704C7D-450C-4B51-99ED-555C8A984391Q28536197-6092CE76-FBE6-47AC-B552-AB0C334C26FDQ33249818-89A31C24-9F77-4825-A630-C8EBD31EBB85Q33302058-742C0C3A-40D0-4EF4-9668-2AED0CB1E9C2Q33361466-5CC8B78B-6ECC-4DFE-9E05-5BD22DC3AEE9Q33385544-0CD21CB2-542E-41E5-961A-DE0B08BF1EB7Q33388447-57D4DF49-40E5-4731-99DD-8C20453E7C4AQ33410375-002CD521-09D2-4692-B87F-929F74AB5B67Q33966855-51AB5960-48EA-4FF1-B53B-F5EF0FF0FF05Q34013315-EE358962-0108-44E9-B90E-42276C1185CFQ34055631-1422DA96-AF39-4C43-8EDE-31F14C44236CQ34109472-22740C3B-05E8-4236-81C8-2D3B46B8AED6Q34146222-19CF129A-7290-4D00-9531-58D399B7AC51Q34257607-5821F9D6-737B-4C34-ACEC-5398A1774B67Q34508252-509AC622-6D07-4732-A7FF-E1E85A402EABQ34656429-8B028EB9-51B3-4BD7-AB16-CC7337358E86Q34686787-277F3028-B83F-4622-A616-FF75EA796778Q34795203-7DD50A4C-0ED7-4950-89AB-2E48E66BF975Q35092304-178D5466-A630-4567-AE85-C5DE285CFE3DQ35198599-96E249CA-5F99-4629-8405-5B3961EAAF20Q35545347-17E8A579-7A4F-48BB-89D0-9769D012D235Q35634068-DA106CA8-C2E4-4CC8-9A3C-56697012F5C0Q35739676-E5D028D3-F2C2-42D9-B178-AEBBD78EEB34Q35782828-B33BCAA8-C68E-4A9D-81E7-E194CF78EEF9Q35844494-87906760-4709-4A7B-B5A7-FD0F4A644C6CQ35855571-663A1C4B-5F26-44C1-864F-EAC8CB77F81CQ35856765-3EFC9F02-AC3D-4A32-B135-6AA97E53E49CQ35913058-A440AF9D-145A-426D-95F8-033DF0021A3BQ36053511-8883F37E-5935-49C6-8A64-F750A837682FQ36303155-20877F73-A86A-44DD-868B-FFD7B5B4E16BQ36318525-F7588329-9884-4EFD-B934-4F7A91866817Q36429727-4B35AADF-E801-4C98-87F9-A94F4138C766Q36537920-049FFA20-CE93-4AF1-9F8F-961DF7186214Q36559414-0D410E4A-4A2E-42A6-BF8E-4F7AB019FFBCQ36572545-2081C39C-C166-46E0-8E59-B314BF098BDB
P2860
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@ast
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@en
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@nl
type
label
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@ast
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@en
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@nl
prefLabel
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@ast
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@en
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@nl
P2093
P356
P1476
Rational development of histone deacetylase inhibitors as anticancer agents: a review.
@en
P2093
Jürgen Venitz
Milin R Acharya
William D Figg
P304
P356
10.1124/MOL.105.014167
P577
2005-06-14T00:00:00Z